Silber, Sigmund; Windecker, Stephan; Vranckx, Pascal; Serruys, Patrick W; RESOLUTE All Comers investigators, (2011). Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet, 377(9773), pp. 1241-7. London: Elsevier 10.1016/S0140-6736(11)60395-4
Full text not available from this repository.In the RESOLUTE All Comers trial, the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus-eluting stent for the primary stent-related endpoint of target lesion failure (cardiac death, target vessel myocardial infarction, and ischaemia-driven target lesion revascularisation) at 1 year. However, data for long-term safety and efficacy from randomised studies of new generation drug-eluting coronary stents in patients treated in routine clinical practice are scarce. We report the prespecified 2-year clinical outcomes from the RESOLUTE All Comers trial.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Windecker, Stephan |
ISSN: |
0140-6736 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:21 |
Last Modified: |
05 Dec 2022 14:06 |
Publisher DOI: |
10.1016/S0140-6736(11)60395-4 |
PubMed ID: |
21459430 |
Web of Science ID: |
000289597300030 |
URI: |
https://boris.unibe.ch/id/eprint/7231 (FactScience: 212419) |